USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONS
USE OF A NEW HEPARINOID AS ANTICOAGULANT DURING ACUTE HAEMODIALYSIS OF PATIENTS WITH BLEEDING COMPLICATIONS
复制标题
在出血并发症患者的急性血液透析期间使用新型肝素作为抗凝剂
DOI：
10.1016/s0140-6736(83)91326-0
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
P. Ockelford
中科院分区：
文献类型：
--
作者：
C. Henny;J. T. Gate;H. Bronswijk;H. Cate;S. Surachno;J. Wilmink;P. Ockelford
Org 10172, a new, natural heparinoid, was used as the sole anticoagulant in twelve patients with acute or acute-on-chronic renal failure, who underwent haemodialysis 55 times. All patients had either intercurrent bleeding or a high risk of severe haemorrhagic complications if given standard heparin therapy. After a single loading dose of 300-600 mg of Org 10172, plasma anti-Xa levels in the range 0·42 - 0·93 U/ml were achieved. All haemodialysis runs were completed without adverse side-effects. There were no haemorrhagic complications and deposition of125I-fibrinogen on the renal dialysis membrane was successfully inhibited in the 4 patients in whom this was studied. Org 10172 seems to prevent thrombosis during renal haemodialysis. It may have a lower risk/benefit ratio than other anticoagulants, such as heparin, in patients at high risk of haemorrhagic complications undergoing haemodialysis
